We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLite Strategy, Inc.

Lite Strategy, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.9235 USD -0.06 ( 6.25%)
Last update at 2026-11-12T15:42:00Z
VOLUME
114779
Market Cap
37.09M

Momentum Score

…

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.91
Low
0.96
High
52 Week Price Range
0.69
Low
2.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public filings and company disclosures provide limited information on Lite Strategy, Inc.'s operating business, so its core activities are not well described in public sources. Because detailed strategy and revenue drivers are not disclosed, major long-term growth drivers are unclear; investors may find the company attractive for potential upside if management announces clear operations or strategic transactions and for Nasdaq liquidity.

Key investment risks are limited public disclosure and an unclear operating history, potential need for additional financing and dilution, low institutional coverage and small-cap liquidity and execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.99
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-1.97M
Debt / Equity
0.52
ROE
-159.26%
Net Debt
-18.01M
ROCE
-103.09%
Diluted EPS TTM
-2.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -15.95M 17.78M -31.84M -54.45M -41.31M
Net income -15.95M 17.78M -31.84M -54.45M -41.31M
Selling general administrative 13.53M 23.30M 33.13M 30.54M 24.41M
Gross profit -0.37M 65.30M 48.82M 40.70M 33.39M
Reconciled depreciation 0.37M 0.38M 0.39M 0.33M 0.28M
Ebit -17.45M 25.44M -36.76M -75.48M -41.31M
Ebitda -17.09M 25.82M -36.38M -75.16M -41.02M
Depreciation and amortization 0.37M 0.38M 0.39M 0.33M 0.28M
Operating income -17.45M 14.54M -36.76M -75.48M -60.42M
Other operating expenses 17.45M 50.76M 85.58M 116.18M 95.22M
Tax provision - - - 0.00M 0.01M
Interest income 1.03M 3.28M 3.35M 0.28M 0.51M
Net interest income 1.03M 3.28M 3.35M 0.28M 0.51M
Income tax expense - - - - 0.01M
Total revenue 0.00M 65.30M 48.82M 40.70M 34.80M
Total operating expenses 17.09M 50.76M 85.58M 116.18M 93.81M
Cost of revenue 0.37M 0.38M 1.81M 1.24M 1.41M
Total other income expense net 1.51M 3.24M 4.93M 21.03M 19.12M
Net income from continuing ops -15.95M 17.78M -31.84M -54.45M -41.31M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 18.29M 41.38M 120.81M 177.84M 174.10M
Other current assets 0.27M 2.42M 6.75M 3.83M 3.81M
Total liab 1.35M 8.36M 96.19M 125.43M 124.63M
Total stockholder equity 16.93M 33.02M 24.62M 52.41M 49.47M
Other current liab 1.18M 5.19M 12.46M 10.82M 8.40M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -404.16M -388.22M -406.00M -374.16M -319.70M
Cash 18.01M 3.71M 16.91M 15.74M 8.54M
Total current liabilities 1.35M 8.36M 20.34M 24.44M 20.21M
Current deferred revenue - - 0.32M 4.83M 4.53M
Net debt -18.01M -3.71M -4.18M -6.10M -0.24M
Short term debt - - 1.43M 0.87M 0.93M
Short long term debt total - - 12.73M 9.64M 8.30M
Other stockholder equity 421.10M 421.24M 430.62M 426.57M 369.17M
Total current assets 18.29M 40.77M 107.53M 167.13M 164.82M
Short term investments 0.00M 34.64M 83.79M 137.51M 144.88M
Net receivables - - 0.09M 10.04M 7.58M
Accounts payable 0.18M 3.17M 6.13M 7.92M 6.36M
Non current assets total 0.00M 0.61M 13.28M 10.71M 9.28M
Capital lease obligations - 0.00M 12.73M 9.64M 8.30M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 35.15M 49.14M 53.69M 6.89M 24.71M
Total cashflows from investing activities 35.15M 49.14M 53.69M 6.89M 24.71M
Total cash from financing activities 0.00M -11.87M -0.04M 49.05M 3.47M
Net income -15.95M 17.78M -31.84M -54.45M -41.31M
Change in cash 14.31M -13.20M 1.17M 7.20M -3.79M
Begin period cash flow 3.71M 16.91M 15.74M 8.54M 12.33M
End period cash flow 18.01M 3.71M 16.91M 15.74M 8.54M
Total cash from operating activities -20.84M -50.47M -52.48M -48.75M -31.96M
Issuance of capital stock - - 0.00M 52.33M 3.20M
Depreciation 0.37M 0.38M 0.39M 0.33M 0.28M
Other cashflows from investing activities 0.01M - - - -
Dividends paid 0.00M 11.66M 0.00M - -
Change to account receivables - 0.09M 9.96M -2.46M 15.70M
Other cashflows from financing activities - -0.21M -0.04M -3.27M -
Capital expenditures 0.00M 0.01M 0.04M 0.48M 0.71M
Change in working capital -4.85M -84.28M -24.95M 16.88M 16.94M
Stock based compensation -0.14M 2.28M 3.59M 8.35M 10.24M
Other non cash items -0.27M 13.36M 0.33M -19.84M -7.88M
Free cash flow -20.84M -50.48M -52.52M -49.23M -32.67M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LITS
Lite Strategy, Inc.		 -0.06
6.25%		 0.92 - 4.62 0.31 0.69 0.81 2.38
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

9920 Pacific Heights Blvd., San Diego, CA, United States, 92121

858 369 7100

https://www.litestrategy.com

4

Name Title Year Born
Mr. Justin J. File CPA CEO, CFO, Corporate Secretary & Director 1970
Ms. Anne Frese Chief People Officer NA
Dr. Robert D. Mass M.D. Strategic Advisor 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…